50 citations
,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
April 2021 in “IntechOpen eBooks” Androgens, male hormones, affect physical and mental functions, with a decrease leading to health issues like muscle loss, bone disease, and depression, and more research is needed on long-term effects and treatments.
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
64 citations
,
June 1995 in “Steroids” Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.
16 citations
,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
26 citations
,
December 1981 in “British journal of dermatology/British journal of dermatology, Supplement” Cyproterone acetate reduced hair growth in most hirsute females and made hair softer, thinner, and lighter.
January 2021 in “International Journal of Dermatology” Possible link between COVID-19 and hair loss; more research needed.
December 2015 in “Вестник дерматологии и венерологии” Men with male pattern baldness may not have different hormone levels, but their hair follicles are likely more sensitive to hormones.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
6 citations
,
October 1993 in “Endocrinology” Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
July 2001 in “APMIS. Acta pathologica, microbiologica et immunologica Scandinavica./APMIS” Male children's genital development issues can be caused by genetic mutations or environmental factors affecting hormone action.
100 citations
,
September 2017 in “Molecular and Cellular Endocrinology” Male hormones and their receptors play a key role in hair loss and skin health, with potential new treatments being explored.
24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
3 citations
,
December 2014 in “Elsevier eBooks” Male hormones and their interactions are crucial for male sexual development and characteristics.
4 citations
,
May 2022 in “Genes & Diseases”
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
8 citations
,
April 1991 in “European journal of endocrinology” 3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.
1 citations
,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
October 2025 in “Journal of the Endocrine Society” Anastrozole can cause increased testosterone, leading to symptoms like hair growth and thinning.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
36 citations
,
June 2014 in “PLOS ONE” Finasteride, a hair loss drug, may cause long-term sexual side effects due to changes in hormone receptor levels.
1 citations
,
August 2002 in “Zeitschrift für Hautkrankheiten” Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.